OA
CRSP icon

Operose Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Operose Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
202
-1,812
-90% -$95.5K ﹤0.01% 406
2026
Q1 		$95.8K Buy
2,014
+1,812
+897% +$95.6K 0.02% 226
2025
Q4 		$10.6K Hold
202
– – ﹤0.01% 377
2025
Q3 		$13.1K Hold
202
– – ﹤0.01% 345
2025
Q2 		$9.82K Hold
202
– – ﹤0.01% 335
2025
Q1 		$6.87K Hold
202
– – ﹤0.01% 338
2024
Q4 		$7.95K Hold
202
– – ﹤0.01% 323
2024
Q3 		$9.49K Hold
202
– – ﹤0.01% 499
2024
Q2 		$10.9K Hold
202
– – ﹤0.01% 439
2024
Q1 		$13.8K Hold
202
– – ﹤0.01% 439
2023
Q4 		$12.6K Hold
202
– – 0.01% 430
2023
Q3 		$9.17K Buy
202
+2
+1% +$103 ﹤0.01% 589
2023
Q2 		$11.2K Hold
200
– – 0.01% 274
2023
Q1 		$9.05K Buy
+200
New +$9.71K ﹤0.01% 270

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Operose Advisors's CRSP Position: Q2 2026 in Review

Operose Advisors reduced its CRISPR Therapeutics (CRSP) stake by 90% in Q2 2026, selling an estimated $95.5K and leaving 202 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #406.

Operose Advisors first reported a position in CRSP in Q1 2023 and has held it in 14 quarters since. The position peaked at $95.8K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Operose Advisors held 202 shares of CRISPR Therapeutics worth $11K as of Q2 2026.
  • Operose Advisors sold 1,812 CRISPR Therapeutics shares in Q2 2026, an estimated $95.5K.
  • CRISPR Therapeutics made up ﹤0.01% of Operose Advisors's portfolio in Q2 2026, its #406 holding.
  • Operose Advisors first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Operose Advisors's CRISPR Therapeutics position peaked at $95.8K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.